Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bacillus coagulans gbi-30
- Development stage
- Preclinical
- Lead developer
- Ganeden
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bacillus coagulans GBI-30, also known by the brand name GanedenBC30, is a patented, spore-forming probiotic bacterial strain. [3, 4, 11] Its ability to form a protective spore allows it to survive harsh conditions, including stomach acid and manufacturing processes, enabling it to germinate and become active in the intestines. [6, 16] Developed by Ganeden and now part of Kerry Group's portfolio, this strain is used as a functional ingredient in a wide range of foods, beverages, and supplements. [1, 5] Clinical research has shown that Bacillus coagulans GBI-30 can help support digestive health, immune function, and protein absorption and utilization. [4, 6, 17] Studies have explored its effects on conditions like irritable bowel syndrome (IBS), exercise-induced muscle damage, and its potential to modulate the gut-brain axis, as seen in trials for major depressive disorder. [6]
- Brand names
- GanedenBC30GanedenBC-30GanedenBC 30
- Other names
- Bacillus coagulans GBI-30, 6086
Beyond the preview
Go deeper on bacillus coagulans gbi-30.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bacillus coagulans gbi-30.